Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Simotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Jiangsu Simcere Pharmaceutical
- 06 Jun 2017 Status changed from recruiting to completed, as per an abstract presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2015 Interim results in 15 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.